{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-06T06:35:49.869851+00:00","company":{"ticker":"PROF","cik":1628808,"company_name":"Profound Medical Corp."},"pagination":{"limit":100,"returned":2,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"c1e843fee7e9fcad965c140ab1437c6bc7b3c8ab","cik":1628808,"ticker":"PROF","company_name":"Profound Medical Corp.","filed_at":"2026-05-07T23:59:59+00:00","payload":{"eps_text":"$0.19 per common share","guidance_signal":"initiated","item_codes_triggered":["2.02"],"net_income_text":"$7.0 million","period_text":"the first quarter ended March 31, 2026","report_date":"2026-05-07","result_type":"reported_results","revenue_text":"$5.3 million"},"claim":"Profound Medical Corp. reported the first quarter ended March 31, 2026 results: revenue $5.3 million, net income $7.0 million, EPS $0.19 per common share. Guidance initiated.","evidence_excerpt":"For the quarter ended March 31, 2026, Profound recorded revenue of approximately $5.3 million","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001171843-26-003160","anchor_url":"https://secwatch.observer/filing/0001171843-26-003160#claim-c1e843fee7e9fcad965c140ab1437c6bc7b3c8ab","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628808/000117184326003160/0001171843-26-003160-index.htm"},{"fact_type":"material_agreement","fact_key":"ad49fce4352b0921702da8b4be34f8437e191826","cik":1628808,"ticker":"PROF","company_name":"Profound Medical Corp.","filed_at":"2025-12-31T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Subscription Agreement","agreement_type":"equity_purchase","counterparty":"certain Canadian investors","effective_date":"2025-12-30","item_codes_triggered":["1.01"],"value_text":"aggregate gross proceeds of $6.45 million"},"claim":"Profound Medical Corp. entered into Subscription Agreement with certain Canadian investors valued at aggregate gross proceeds of $6.45 million (effective 2025-12-30).","evidence_excerpt":"On December 30, 2025, Profound Medical Corp. (the “Company”) entered into a subscription agreement (the “Subscription Agreement”) with certain Canadian investors (the “Investors”) providing for the private placement of an aggregate of 921,428 shares of the Company’s common shares (the “Shares”), at a per share purchase price of $7.00 (the “Offering”) for aggregate gross proceeds of $6.45 million.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-25-125344","anchor_url":"https://secwatch.observer/filing/0001104659-25-125344#claim-ad49fce4352b0921702da8b4be34f8437e191826","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628808/000110465925125344/0001104659-25-125344-index.htm"}]}